Competing interests
MH, Hoffmann-la
O.A.S.: Advisory Board (Ascentage, AstraZeneca, AbbVie, BeiGene, Eli Lilly, Gilead, Janssen, Roche), speaker honoraria (Adaptive, AstraZeneca, AbbVie, BeiGene, Eli Lilly, Gilead, Janssen, Roche), research funding (BeiGene, AbbVie, Janssen, Roche). H.Y.J.: Employment with Genentech/Hoffmann-la Roche. S.B.: Employment with Genentech/Hoffmann-la Roche. A.K.: Employment with Hoffmann-la Roche. Y.C.: Employment with Genentech/Hoffmann-la Roche. A.M.F.: reports personal fees from Celgene, Janssen, Hoffmann-La Roche. E.T.: Advisory Board (Abbvie, Janssen-Cilag, BeiGene), speaker honoraria (AstraZeneca, Abbvie, BeiGene, Gilead, Janssen, Roche), research funding (Roche, Abbvie, Gilead). C.S.: Speaker honoraria (AstraZeneca, AbbVie). M.R.: reports grants from F.Hoffman-La Roche Ltd; personal fees from F. Hoffmann-La Roche Ltd, AbbVie. K.A.K.: reports grants from F. Hoffmann-La Roche Ltd, Abbvie, during the conduct of the study; personal fees from F. Hoffmann-La Roche Ltd, AbbVie. B.C.: Employment with AbbVie. C.P.P.: Speaker honoraria (AstraZeneca, Pfizer) Research Funding (Gilead Sciences) Advisory Board (Abbvie) J.P.: Employment with Genentech/Hoffmann-la Roche. B.E.: Grants and personal fees from F. Hoffmann-La Roche Ltd, AbbVie, AstraZeneca, BeiGene, and Janssen, personal fees from Celgene, Novartis, ArQule, Gilead, Oxford Biomedica (UK), Adaptive Biotechnologies, Hexal. S.S.: Grants, personal fees and non-financial support from AbbVie, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche Ltd, Janssen, Novartis, Pharmacyclics, Sunesis, Verastem. Y.J.: Employment with Genentech/Hoffmann-la Roche, stock (Genentech). MH: Honoraria (Roche, Janssen, AbbVie, Gilead Sciences, AstraZeneca), Consulting or Advisory Role (Janssen, AbbVie, Gilead Sciences, Genentech/Roche, AstraZeneca), Speakers’ Bureau: Janssen, AbbVie, Gilead Sciences, Roche/Genentech, AstraZeneca), Research Funding (Roche, AbbVie, Janssen, Gilead Sciences, AstraZeneca), Travel, Accommodations, Expenses (Roche, Janssen). K.F.: Advisory Board (AstraZeneca, AbbVie), speaker honoraria (AbbVie, Roche), research funding (AbbVie, Roche). The remaining authors declare no other competing interests.